
€16.5m to advance automated, microfluidic CGT therapy
Astraveus, providers of modular, microfluidic cell foundries for cell and gene therapy (CGT) manufacturing, has completed an oversubscribed €16.5 million Series Seed financing led by AdBio partners, co-syndicated with M Ventures, Johnson & Johnson Innovation – JJDC Inc., and Bpifrance Large Venture. Astraveus’ Lakhesys platform is an end-to-end cell foundry… Read More















